Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma
Filed with Euronext · · 3 pages · English
Story so far
- Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
- Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
- Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients
Earlier from Nicox
- Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension
- Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
- Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company
- Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
- Reminder: Nicox June 2024 Warrants will expire June 19, 2026
Later from Nicox
- Nicox annonce l’extension de son horizon de trésorerie
- Nicox Announces Extension of Cash Runway
- Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 470
- Nicox Announces NCX 470 NDA in China Accepted for Review
- Nicox: Les données sur NCX 470 seront présentées lors du Congrès annuel 2026 de l’AAOpt
Follow Nicox into a list and get an email when it puts out news.
Follow Nicox